Bristol-Myers Squibb Co vs PPG Industries, Inc. — how do they compare? Bristol-Myers Squibb Co trades at $57 (market cap $116.30B), while PPG Industries, Inc. trades at $114.66 (market cap $25.56B). The key difference: Bristol-Myers Squibb Co is far larger — about 4.6× PPG Industries, Inc.'s market cap, and Bristol-Myers Squibb Co pays the higher dividend (4.42%). Which is the better fit depends on your goals.
| BMY | PPG | |
|---|---|---|
Market Cap | $116.30B | $25.56B |
Sector | Health | Basic Materials |
52-Week High | $62.37 | $131.56 |
52-Week Low | $42.60 | $94.34 |
Enterprise Value | $152.24B | $31.66B |
Dividend Yield | 4.42% | 2.48% |
Signals from Pluang's Aura AI — not financial advice
Bristol Myers Squibb (BMY) trades at $59.34, up 3.06% today, with a bullish technical signal and consistent earnings beats. The stock shows strong profitability with a 15.01% net margin and 38.84% ROE, though debt levels have risen. Recent FDA acceptance for mezigdomide in multiple myeloma highlights pipeline progress. Analysts are mixed with a $60 consensus target, slightly above current price.
BMY offers value with a P/E of 16.62 and a safe 4.3% dividend yield, but faces patent cliff risks and pricing pressures. Earnings growth and pipeline execution are key catalysts, while high debt and competitive threats require monitoring. The stock presents a balanced opportunity for income-focused investors with moderate risk tolerance.
PPG Industries trades at $113.84, down 2.5% on the day, with a bullish technical signal despite near-term volatility. The stock shows strong profitability with a net margin of 9.83% and ROE of 21.09%, supported by consistent earnings beats in recent quarters. Recent news highlights innovation in aerospace and marine coatings, alongside a sustainable dividend profile. Valuation ratios appear reasonable with a P/E of 16.31 and P/S of 1.6.
The outlook remains positive given analyst consensus favoring a buy rating and a $131.75 price target, implying significant upside. Risks include volume softness and margin pressure, but robust cash flow and strategic innovations provide a cushion. The stock presents a value opportunity with growth catalysts from new product launches and market expansion.
Trailing returns across standard periods
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →PPG is a global producer of coatings. The company is the world's largest producer of coatings after the purchase of selected Akzo Nobel assets. PPG's products are sold to a wide variety of end users, including the automotive, aerospace, construction, and industrial markets. The company has a footprint in many regions around the globe, with less than half of sales coming from North America in recent years. PPG is focused on its coatings and specialty products and expansion into emerging regions, as exemplified by the Comex acquisition.
Read more on PPG →